Memorial Sloan Kettering Cancer Center 1275 York Ave, New York, NY 10065 (212)6392000 (phone), (646)4220298 (fax)
Education:
Medical School University of Puerto Rico School of Medicine Graduated: 1974
Conditions:
Thyroid Cancer
Languages:
English
Description:
Dr. Carrasquillo graduated from the University of Puerto Rico School of Medicine in 1974. He works in New York, NY and specializes in Nuclear Medicine. Dr. Carrasquillo is affiliated with Bellevue Hospital Center, Memorial Sloan Kettering Cancer Center, New York Presbyterian Hospital Columbia University Medical Center and New York Presbyterian Westchester Division.
Steven M. Larson - Washington DC Ronald Finn - Bethesda MD Jorge A. Carrasquillo - Rockville MD James C. Reynolds - Rockville MD Ronald D. Neumann - Potomac MD Martin C. Graham - Larchmont NY Keith S. Pentlow - Forest Hills NY
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC
International Classification:
A61K 4902 C07K 1500
US Classification:
424 11
Abstract:
A composition comprises an antigen-specific antibody or antigen-binding fragment thereof labeled with Iodine-124 at a site other than, and which does not significantly interfere with, the antibody-antigen binding site. An in vivo method of radiotherapy directed to an antigenic site comprises administering to a subject in need of the therapy an amount of the antigen-specific composition described above effective to attain a reduction of the size of a tumor associated with the antigen. An in vivo method for detecting and localizing an antigenic site in a subject in need of such detection comprises administering to the subject an amount of the antigen-specific composition of the invention effective to localize the antigen-antibody binding site and scanning the subject's body with a positron-emitter detector to attain the localization of the site. An in situ method of radiotherapy directed to an antigenic site in a subject in need of such therapy comprises detecting and localizing the site by the in vivo method described above and thereafter in situ delivering a positron-emitting labeled antibody chelate capable of binding to either the I-124 labeled antibody or fragment thereof, or to the antigen at a site other than the antibody-antigen binding site.